Double patenting between parent and divisional applications in Southeast Asia
When filing divisional applications in Southeast Asia, rules and limits vary across jurisdictions and patentees have several major differences to consider. These include the extent of allowable overlap with the...
When filing divisional applications in Southeast Asia, rules and limits vary across jurisdictions and patentees have several major differences...
Read More
Pharmaceutical Patent disputes in China | The nuances of “offer to sell”
The application of Bolar exceptions and the definition of "offer to sell" have long been contentious issues in the pharmaceutical industry in China. Article 11 of the Chinese Patent Law...
The application of Bolar exceptions and the definition of "offer to sell" have long been contentious issues in the pharmaceutical...
Read More
Storm clouds around AI patentability
With the global technology race to create large scaled AI learning systems utilising Artificial Neural Networks (ANNs) and Reinforcement Learning, there has been a general reluctance of patent offices...
With the global technology race to create large scaled AI learning systems utilising Artificial Neural Networks (ANNs) and Reinforcement...
Read More
Landmark IP Decision by China Supreme Court
The Supreme Court of the P.R. China recently announced the decision of an appeal case involving a dispute over patents and technology secrets related to new energy vehicle chassis...
The Supreme Court of the P.R. China recently announced the decision of an appeal case involving a dispute over...
Read More
Australia second in cleantech growth – tips for in-house counsel
With a landscape so compatible with cleantech solutions, no wonder Australia is a hotbed for innovation. We discuss this and provide tips for IP professionals working in the sector.
With a landscape so compatible with cleantech solutions, no wonder Australia is a hotbed for innovation. We discuss this...
Read More
Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
IAM Patent 1000 2024
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding result in multiple countries. We are delighted to announce the...
Spruson & Ferguson has once again been recognised in the 2024 IAM Patent 1000 rankings across the Asia-Pacific, with an outstanding...
Read More
Pharmaceutical patent term extension in Australia
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial importance, and in recent years have become of particular interest...
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial...
Read More